Injection novel medicine for treating systematic lupus erythematosus

A lupus erythematosus and injection technology, applied in allergic diseases, inorganic active ingredients, organic active ingredients, etc., can solve problems such as large side effects and can not be used for a long time, and achieve the effect of strong anti-systemic lupus erythematosus effect

Inactive Publication Date: 2011-03-23
张南 +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs have a certain effect on the treatment of systemic lupus erythematosus, but the side effects are very large and cannot be used for a long time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Injection novel medicine for treating systematic lupus erythematosus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Dissolve 1 mg of arsenic trioxide in normal saline first, then add 40 mg of cinobufacin, stir to dissolve; finally add 40 mg of matrine and 1 mg of borneol, stir evenly to make the color into a light yellow liquid and sterilize it. finished product.

[0021] In the injection of this embodiment, every milliliter contains 1 milligram of arsenic trioxide, 40 milligrams of matrine, 40 milligrams of cinobufacin (containing serotonin at a concentration of 18 micrograms / ml or containing bufocin at a concentration of 25 micrograms / ml) and 1 mg borneol.

Embodiment 2

[0023] Dissolve 5 mg of arsenic trioxide in normal saline first, then add 50 mg of cinobufacin, stir to dissolve; finally add 50 mg of matrine and 5 mg of borneol, stir evenly to make the color into a light yellow liquid and sterilize it. finished product.

[0024] The injection in this example contains 5 mg of arsenic trioxide, 50 mg of matrine, 50 mg of cinobufacin and 5 mg of borneol per milliliter.

[0025] In order to further illustrate the outstanding effect of the injection of the present invention, the prepared single injection is compared with the injection of the present invention to prepare a single arsenic trioxide injection: dissolve arsenic trioxide (white color) with physiological saline, and each milliliter of arsenic trioxide injection contains 1 mg Arsenic trioxide.

[0026] Preparation of matrine oral liquid: dissolve matrine with normal saline, and each milliliter of matrine injection contains 1 mg of matrine.

[0027] Preparation of cinobufacin oral solu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the medicine technical field, which particularly relates to a novel injection drug for treating systemic lupus erythematosus. In the invention, four drugs of arsenic trioxide, matrine, Chinese toad bufotoxin and borneol are mixed according to certain ratio to prepare a novel injection preparation for treating the systemic lupus erythematosus; when the injection preparation is used for tested mice with the systemic lupus erythematosus, the injection preparation has good function of resisting the systemic lupus erythematosus, the obvious synergic action is generated among the four drugs; and because the injection drug can resist side effects caused by the single arsenic trioxide injection liquid, the injection drug is the most promising non-toxic drug for resisting the systemic lupus erythematosus; as the novel injection drug is developed and put into use, the novel injection drug will become a first-choice drug for resisting the systemic lupus erythematosus.

Description

Technical field: [0001] The invention belongs to the technical field of medicines, in particular to an injection for treating systemic lupus erythematosus. Background technique: [0002] Lupus erythematosus is a disease of collagen tissue, that is, the human body's own immune system. "Lupus erythematosus" is divided into two types of lesions, systemic lupus erythematosus and discoid lupus erythematosus, which mostly occur in adolescent and childbearing women, especially young women. The peak incidence is between 15-40 years old, and the ratio of male to female is 1:5-9. It is also seen in children and the elderly, and the difference between male and female incidence is narrowed in children and the elderly, and the ratio of male to female is about 1:2. In addition to heredity, infection, drugs, and environmental factors, the cause of the disease is also related to the endocrine system of the human body, especially female hormones, so it is more common in women. Discoid lupu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K35/56A61P37/02A61P29/00A61K31/4375A61K33/36A61K35/65
Inventor 张南李晓
Owner 张南
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap